UnitedHealthcare SCS/DRG Coverage Update

Coverage Criteria for Implanted Spinal Cord and DRG Stimulation

SCS - Proven indications

Covered when performed according to FDA labeled indications, contraindications, warnings, and precautions and when InterQual SCS insertion medical necessity criteria are met.

Proven/Medically Necessary SCS indications: SCS is proven and medically necessary for Complex Regional Pain Syndrome (CRPS), Painful diabetic neuropathy, and Failed back surgery syndrome when performed per U.S. Food and Drug Administration labeled indications, contraindications, warnings, and precautions and when InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion criteria are met.

Refer to InterQual clinical criteria link in policy.

DRG stimulation - Proven indications

Covered when performed according to FDA labeled indications, contraindications, warnings, and precautions and when InterQual criteria are met.

Proven/Medically Necessary DRG indication: DRG stimulation is proven and medically necessary for Complex Regional Pain Syndrome (CRPS I and CRPS II) when performed per U.S. Food and Drug Administration labeled indications, contraindications, warnings, and precautions and when InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion criteria are met.

Refer to InterQual clinical criteria link in policy.

Unproven / Not medically necessary uses

Not medically necessary / Unproven

SCS unproven indications: SCS is unproven and not medically necessary for chronic intractable back pain without prior spine surgery due to insufficient evidence of efficacy.

Policy explicitly lists this as unproven/not medically necessary.

DRG unproven indications: DRG stimulation is unproven and not medically necessary for all other conditions not specifically listed as proven, including neuropathic pain etiologies where effectiveness and safety are unknown (e.g., cancer pain, postherpetic neuralgia, diabetic peripheral neuropathy, central neuropathic pain) due to insufficient evidence.

Policy states DRG unproven for other conditions; evidence is very low quality and limited.

Evidence synthesis and clinical considerations

Clinical evidence and typical patient populations described in the document

Indications with supportive but low-quality evidence: Various focal neuropathic and regional pain indications (for example CRPS/causalgia, pelvic/groin pain, phantom limb pain, selected post-surgical neuropathic pain) have small trials and observational studies reporting many cohorts with >50% pain reduction, but overall evidence quality is low and at risk of bias.

Supported by multiple systematic reviews and observational studies; limitations include small sample sizes and risk of bias.

Comparative effectiveness: The ACCURATE randomized trial reported higher treatment success for DRG versus traditional dorsal column SCS at three months (81.2% vs 55.7%), and pooled analyses report responder rates around 63% at 12 months in pooled samples.≥ 50% pain reduction (responder definition used in cited trials)

Short-term superiority observed in specific RCT for CRPS; longer-term data needed.

Safety signals and complications: Reported complications include device-related events (lead migration/fracture, IPG pocket pain, overstimulation), and infection rates that vary by stage (trial 1.03%, implant 4.80%, overall 2.82%); revisions carry additional procedural risks.

Coverage rationale and cited guideline-based criteria

Key coverage stances and criteria referenced in this segment include:

DRG for CRPS: DRG stimulation is proven and medically necessary for treating complex regional pain syndrome (CRPS I, CRPS II) when performed according to U.S. Food and Drug Administration labeled indications, contraindications, warnings, and precautions.

Revised policy language clarifies DRG indication for CRPS.

HF10 (Senza) considerations: HF10 therapy (Senza) should be considered for individuals with residual chronic neuropathic back or leg pain of at least 50 mm on a 0–100 mm VAS at least six months after back surgery despite conventional medical management, and who have had a successful stimulation trial assessed by a multidisciplinary team.VAS >= 50 mm; >= 6 months post-surgery

Per NICE guidance referenced in policy.

SCS for low back pain guidance: The 2022 VA/DoD guideline recommended against SCS for patients with low back pain.

This policy designates certain uses of spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation as proven and medically necessary when performed according to U.S. Food and Drug Administration labeled indications and when InterQual SCS insertion clinical criteria are met. Conversely, SCS and DRG procedures are considered unproven and not medically necessary for indications not supported by sufficient evidence. Specifically, implanted electrical spinal cord stimulators are listed as not medically necessary for chronic intractable back pain without prior spine surgery, and DRG stimulation is considered unproven for conditions other than those explicitly identified as proven in this policy.

DRG stimulation has shown treatment benefits for focal neuropathic conditions—most notably Complex Regional Pain Syndrome (CRPS I and II)—and some small studies and reviews report improved pain, quality of life, and patient satisfaction versus baseline or compared with traditional SCS in select cohorts. However, the overall evidence base is limited by very low to low quality, small sample sizes, retrospective designs, and heterogeneity of patient populations. The policy therefore recognizes DRG stimulation as proven and medically necessary only for CRPS (per FDA labeling and InterQual criteria) and considers its effectiveness and safety for other neuropathic etiologies (for example, cancer-related neuropathic pain, postherpetic neuralgia, diabetic peripheral neuropathy, and certain central neuropathic pains) to be unknown or unproven pending higher-quality studies.

The 2022 VA/DoD Clinical Practice Guideline for low back pain issued a recommendation against the use of SCS for patients with low back pain. This guideline recommendation is cited in the policy as a notable guideline-based position informing the coverage stance on SCS for isolated low back pain.

Consistent with the evidence assessment summarized in this policy, implanted electrical spinal cord stimulators are explicitly listed as unproven and not medically necessary for chronic intractable back pain without prior spine surgery due to insufficient evidence of efficacy for that indication.

The VA/DoD 2022 guideline recommendation against SCS for low back pain is referenced in this policy and may inform noncoverage decisions for isolated low back pain indications; clinicians should note this guideline when documenting rationale for or against SCS in such patients.

There is a recognized conflict between some device-specific approvals, trial evidence for certain SCS waveforms, and guideline recommendations. While some SCS therapies have randomized trial support for postsurgical neuropathic pain syndromes and certain device-specific indications, the VA/DoD guideline explicitly recommends against SCS for low back pain—supporting the policy’s approach to consider SCS for low back pain as not medically necessary when performed for isolated low back pain without other supported indications.

Prior Conservative Management and Trial Requirements

Document prior conservative treatments attempted

Document prior conservative treatments attempted:

Required documentation of prior conservative therapies: Medical record must document prior unsuccessful conventional pharmacologic and nonpharmacologic interventions attempted for the current pain condition, including relevant durations and responses (e.g., physical therapy, exercise/rehabilitation, medication trials, interventional procedures).

DRG and SCS studies and reviews commonly involved patients who failed other treatment modalities; document specifics in the record.

Failure of conventional medical management

Failure of conventional medical management:

Duration of failed conventional management: For certain SCS indications (for example HF10/Senza per NICE), individuals should have persistent symptoms despite conventional medical management for at least 6 months after back surgery prior to consideration of SCS.>= 6 months

Provider Actions, Documentation, and Authorization

Prior Authorization

Check benefit requirements and submit documentation

Check benefit requirements and submit complete medical records with prior authorization requests. Benefit coverage is determined by federal, state, or contractual requirements and applicable laws; submission of records does not guarantee coverage. Prior authorization or review may require additional documentation to demonstrate that the requested service meets clinical criteria.

Submit full medical records to support medical necessity (history, physical exam, diagnostic test results).
Verify member-specific federal/state/contractual benefit terms before proceeding.
Submission of records alone does not authorize payment or guarantee coverage.

Documentation Required

Documentation and PARP compliance (Pennsylvania)

This policy applies to Pennsylvania. Requests that do not meet Pennsylvania Exceptions (PARP) criteria will be evaluated case-by-case. If PARP criteria are not met, provide complete clinical justification and supporting records for consideration under exception review.

Applicable Procedure and Supply Codes

Applicable CPT CodesCPT

63650	Percutaneous implantation of neurostimulator electrode array, epidural.
63655	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
63688	Revision or removal of implanted spinal neurostimulator pulse generator or receiver, with detachable connection to electrode array.

Applicable HCPCS CodesHCPCS

L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8682	Implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension.
L8695	External recharging system for battery (external) for use with implantable neurostimulator, replacement only.

Responder rate threshold used in cited trials

Responder definition used in trialsResponder = ≥ 50% reduction in pain from baseline (measured by NRS or VAS).

Common endpoints reportedTrials and systematic reviews used ≥50% pain relief as the primary responder endpoint at 3–12 month timepoints.

Examples from key studiesDISTINCT and Kapural 10-kHz trials reported responder rates defined as ≥50% pain reduction on NRS or VAS; ACCURATE used ≥50% VAS decrease in its composite endpoint.

Frequency and Replacement Policies

Replacement battery/generator policy

Coverage condition for replacementReplacement battery/generator is covered when the existing device is malfunctioning, cannot be repaired, and is no longer under warranty.

No numeric frequency limitPolicy does not specify a numeric frequency limit or interval for replacement procedures.

Documentation implicationProviders should document device malfunction, attempted repair (if any), and warranty status to support medical necessity.

Imaging and Procedural Assessment Documentation

Documentation Required

Include results of pertinent diagnostic tests/procedures in the chart

Include results of pertinent diagnostic tests or procedures in the medical record (e.g., imaging, nerve conduction studies) when applicable to support medical necessity for SCS/DRG interventions.

Attach relevant imaging reports, EMG/NCS, or other diagnostic test results used in decision-making.
Document interpretation of test results and how they support the treatment plan.

Note

DRG stimulation — emphasize selection and documented trial (no imaging prerequisites specified)

For DRG stimulation, emphasize appropriate patient selection and trial stimulation per guidance; the policy excerpt does not specify additional imaging prerequisites.

Ensure patient selection criteria and trial outcomes are documented.
Imaging requirements are not specified for DRG in this excerpt; focus documentation on selection and trial success.

Definitions and Terminology

Spinal cord stimulation (SCS)

DefinitionSpinal cord stimulation (SCS): implantable electrical stimulator placed epidurally to modulate spinal cord signaling for chronic pain treatment.

Typical indicationsUsed for refractory neuropathic and regional pain syndromes including CRPS, painful diabetic neuropathy, and failed back surgery syndrome when performed per FDA labeling and InterQual criteria.

Clinical use notePolicy references InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion for medical necessity criteria and prior conservative management requirements.

Dorsal root ganglion (DRG) stimulation

DefinitionDorsal root ganglion (DRG) stimulation: targeted electrical stimulation of the dorsal root ganglion to treat focal neuropathic pain, such as complex regional pain syndrome (CRPS).

Primary proven indication

Background and Scope

Spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation are implantable neuromodulation therapies used to treat refractory neuropathic and regional pain syndromes. The policy summarizes randomized controlled trials, systematic reviews, and observational studies that demonstrate benefit in specific populations (for example, CRPS and certain postsurgical neuropathic pain syndromes), while also noting important limitations such as small study size, short follow-up, and risk of bias. As a result, this policy restricts coverage to FDA-labeled indications and cases meeting InterQual clinical criteria, and it emphasizes that DRG stimulation is proven for CRPS I and II but not for most other neuropathic etiologies.

Not Covered / Exclusions

Not covered under this policy are uses lacking sufficient evidence of benefit. Explicit exclusions include: chronic intractable back pain without prior spine surgery for SCS; DRG stimulation for conditions other than CRPS (DRG is proven only for CRPS I and II); and SCS for isolated low back pain in light of the VA/DoD 2022 guideline recommendation against SCS for low back pain. Additionally, the policy notes that effectiveness and safety of DRG stimulation for other neuropathic etiologies (for example, cancer-related neuropathic pain, postherpetic neuralgia, diabetic peripheral neuropathy, and central neuropathic pain etiologies) are unknown or unproven based on current evidence.

OpenPayer

Implanted Electrical Stimulator for the Spinal Cord (for Pennsylvania Only)